Rmb Capital Management, LLC Ionis Pharmaceuticals Inc Transaction History

Rmb Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$53.85 - $65.27 $709,635 - $860,128	-13,178 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$59.06 - $72.15 $455,234 - $556,132	-7,708 Reduced 36.91%	13,178 $789,000
Q2 2019 Aug 13, 2019	SELL	$62.09 - $86.14 $629,716 - $873,631	-10,142 Reduced 32.69%	20,886 $1.34 Million
Q4 2018 Feb 13, 2019	SELL	$43.37 - $59.54 $217,153 - $298,116	-5,007 Reduced 13.89%	31,028 $1.68 Million
Q3 2018 Nov 14, 2018	SELL	$42.88 - $53.7 $107,328 - $134,411	-2,503 Reduced 6.49%	36,035 $1.86 Million
Q2 2018 Aug 13, 2018	SELL	$40.53 - $50.7 $605,923 - $757,965	-14,950 Reduced 27.95%	38,538 $0
Q1 2018 May 14, 2018	SELL	$44.08 - $55.05 $588,644 - $735,137	-13,354 Reduced 19.98%	53,488 $2.36 Million
Q4 2017 Feb 14, 2018	SELL	$50.3 - $64.39 $794,387 - $1.02 Million	-15,793 Reduced 19.11%	66,842 $3.36 Million
Q3 2017 Nov 14, 2017	SELL	$45.56 - $59.57 $21,413 - $27,997	-470 Reduced 0.57%	82,635 $4.19 Million
Q2 2017 Aug 14, 2017	BUY	N/A	83,105	83,105 $4.23 Million

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Rmb Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rmb Capital Management, LLC with notifications on news.